Market revenue in 2023 | USD 517.2 million |
Market revenue in 2030 | USD 919.3 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Regulatory writing & publishing |
Fastest growing segment | Legal Representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services |
Key market players worldwide | Labcorp Holdings Inc, IQVIA Holdings Inc, Icon PLC, Wuxi AppTec Co Ltd, Charles River Laboratories International Inc, Cencora Inc, Pharmexon, Genpact Ltd, Freyr Solutions, PAREXEL |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical regulatory affairs market will help companies and investors design strategic landscapes.
Regulatory writing & publishing was the largest segment with a revenue share of 36.54% in 2023. Horizon Databook has segmented the China pharmaceutical regulatory affairs market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, other services covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most attractive markets for the biopharmaceutical industry. The growing geriatric population and a large pool of middle-income group population are increasing the demand for innovative and cost-effective medicines, which is expected to attract major biopharmaceutical and medical device companies.
Seeking approval for new drugs is a primary challenge faced by biopharmaceutical companies, as a clinical trial application process requires 12 to 24 months. In contrast, approval process may require more than 6 years. Along with national approvals, the new drug requires approval at the provincial and/or city level, which may require additional 4 to 5 years.
Horizon Databook provides a detailed overview of country-level data and insights on the China pharmaceutical regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into China pharmaceutical regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account